#United States #Las Vegas #Tulavi #Hydrogel Cap #Surgical Device

Tulavi Therapeutics to Exhibit the allay™ Hydrogel Cap

Tulavi Therapeutics has made a notable advancement in the medical device sector by being selected to showcase their innovative allay™ Hydrogel Cap at the upcoming Vizient Innovative Technology Exchange, scheduled for September 17 in Las Vegas. This event is a premier platform, allowing select suppliers to present their groundbreaking products and services to healthcare leaders and clinical experts from Vizient's vast network of hospital clients.

The allay™ Hydrogel Cap stands out as the first surgical device of its kind, specifically engineered to safeguard transected nerves and mitigate the risk of neuroma formation. This is particularly vital, given that the U.S. witnesses around 600,000 amputations and nearly 1.9 million peripheral nerve surgeries annually. When such nerves are damaged, the recovery process can lead to the development of symptomatic neuromas, a condition often accompanied by chronic pain that adversely affects patients' mobility and overall quality of life.

Impressively, the hydrogel cap utilizes a proprietary technology that has previously demonstrated safety in over 5 million patients globally. This novel device is sutureless and entirely absorbable, creating a supportive barrier around the injured nerve. Its design allows for a seamless fit, fostering an environment that promotes nerve healing while concurrently reducing the likelihood of painful neuroma complications. Once placed, the cap remains in situ for an estimated eight months, during which it provides critical protection against axonal escape, a key factor in neuroma formation.

Dr. Josh Vose, CEO of Tulavi Therapeutics, expressed enthusiasm over the opportunity to partake in the Vizient Innovative Technology Exchange, stating, "It’s an honor to be invited to the Vizient Innovative Technology Exchange. Tulavi’s hydrogel-based approach is transformative in the surgical care of amputees and individuals with peripheral nerve injuries. We’re eager to demonstrate how the allay™ Hydrogel Cap enhances clinical outcomes and patient experiences."

This annual exchange not only allows Tulavi to showcase its innovations but also serves as an important interface for healthcare providers to engage with products that have the potential to elevate clinical care and reshape healthcare business models. Kelly Flaharty, senior director of contract services at Vizient, remarked, "The Innovative Technology Exchange provides a unique opportunity for healthcare providers to explore innovations that can significantly impact both clinical outcomes and business structures. We are thrilled to welcome Tulavi Therapeutics to our exchange."

The Vizient Innovative Technology Program could be a game-changer for upcoming medical technologies. Since its inception in 2003, Vizient has reviewed over 1,700 product submissions, affirming its commitment to enhancing healthcare delivery through innovative solution offerings.

Based in Los Gatos, California, Tulavi Therapeutics focuses on revolutionizing peripheral nerve surgery through unique biomaterial solutions. Their proprietary hydrogel technology represents a significant evolution in addressing the unmet needs associated with nerve injuries. With a commitment to improving patient outcomes and setting new standards for surgical care, Tulavi is poised to make considerable strides in the field of medical devices aimed at nerve repair and protection.